Adrenergic blockade in diabetic and uninephrectomized rats: effects on renal size and on renal and urinary contents of epidermal growth factor
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Adrenergic blockade in diabetic and uninephrectomized rats : effects on renal size and on renal and urinary contents of epidermal growth factor. / Thulesen, J; Poulsen, Steen Seier; Jørgensen, P E; Nexø, Ebba.
In: Nephron, Vol. 81, No. 2, 02.1999, p. 172-82.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Adrenergic blockade in diabetic and uninephrectomized rats
T2 - effects on renal size and on renal and urinary contents of epidermal growth factor
AU - Thulesen, J
AU - Poulsen, Steen Seier
AU - Jørgensen, P E
AU - Nexø, Ebba
PY - 1999/2
Y1 - 1999/2
N2 - The present study reports on the effects of adrenergic blocking agents on the renal growth and on the renal content and urinary excretion of epidermal growth factor (EGF) in streptozotocin-induced diabetic or uninephrectomized rats. Diabetic and uninephrectomized rats were allocated to groups treated with either saline or adrenergic antagonists and compared to controls and sham-operated controls, respectively. 24-hour urine samples were obtained on days 7, 14, and 21 and renal tissue samples on day 21. The 24-hour urinary excretion of EGF from controls and saline-treated diabetic rats was comparable. In adrenergic antagonist treated diabetic rats, it was reduced by at least 40% throughout the study period. Uninephrectomy caused a 50% reduction in the urinary excretion of EGF. This was not influenced by treatment with an adrenergic antagonist. After 3 weeks, saline-treated diabetic rats had an increase of 33% in kidney weight when compared to controls. The adrenergic antagonist treated diabetic groups had a significantly lower increase of 15%. Postnephrectomized renal growth was not affected by adrenergic antagonists. The total renal content of EGF was comparable in the saline-treated diabetic group and the control group, but was reduced by approximately 50% in the kidneys from the adrenergic antagonist treated diabetic groups. Renal EGF mRNA levels were also reduced in adrenergic antagonist treated diabetic rats. In contrast to diabetes, the renal growth following nephrectomy was not affected by adrenergic blocking agents. These results provide evidence for fundamental differences between diabetes-related renal growth and that observed in compensation to nephrectomy and suggest a connection between adrenergic activity, renal growth, and EGF in diabetes.
AB - The present study reports on the effects of adrenergic blocking agents on the renal growth and on the renal content and urinary excretion of epidermal growth factor (EGF) in streptozotocin-induced diabetic or uninephrectomized rats. Diabetic and uninephrectomized rats were allocated to groups treated with either saline or adrenergic antagonists and compared to controls and sham-operated controls, respectively. 24-hour urine samples were obtained on days 7, 14, and 21 and renal tissue samples on day 21. The 24-hour urinary excretion of EGF from controls and saline-treated diabetic rats was comparable. In adrenergic antagonist treated diabetic rats, it was reduced by at least 40% throughout the study period. Uninephrectomy caused a 50% reduction in the urinary excretion of EGF. This was not influenced by treatment with an adrenergic antagonist. After 3 weeks, saline-treated diabetic rats had an increase of 33% in kidney weight when compared to controls. The adrenergic antagonist treated diabetic groups had a significantly lower increase of 15%. Postnephrectomized renal growth was not affected by adrenergic antagonists. The total renal content of EGF was comparable in the saline-treated diabetic group and the control group, but was reduced by approximately 50% in the kidneys from the adrenergic antagonist treated diabetic groups. Renal EGF mRNA levels were also reduced in adrenergic antagonist treated diabetic rats. In contrast to diabetes, the renal growth following nephrectomy was not affected by adrenergic blocking agents. These results provide evidence for fundamental differences between diabetes-related renal growth and that observed in compensation to nephrectomy and suggest a connection between adrenergic activity, renal growth, and EGF in diabetes.
KW - Adrenergic alpha-Antagonists
KW - Adrenergic beta-Antagonists
KW - Animals
KW - Blood Glucose
KW - Diabetes Mellitus, Experimental
KW - Diabetic Nephropathies
KW - Epidermal Growth Factor
KW - Female
KW - Gene Expression
KW - In Situ Hybridization
KW - Kidney
KW - Kidney Function Tests
KW - Nephrectomy
KW - Oligonucleotide Probes
KW - Organ Size
KW - Prazosin
KW - Propranolol
KW - RNA, Messenger
KW - Rats
KW - Rats, Wistar
M3 - Journal article
C2 - 9933753
VL - 81
SP - 172
EP - 182
JO - Nephron - Clinical Practice
JF - Nephron - Clinical Practice
SN - 1660-8151
IS - 2
ER -
ID: 47486618